Novartis Announces FDA Has Approved Cosentyx To TreatModerate To Severe Hidradenitis Suppurativa In Adults
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Novartis' Cosentyx for the treatment of moderate to severe Hidradenitis Suppurativa in adults. This approval could potentially increase Novartis' market share in the pharmaceutical industry.
October 31, 2023 | 8:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA approval of Cosentyx for treating Hidradenitis Suppurativa could potentially increase Novartis' market share and revenue.
FDA approval of a new drug means that Novartis can now market and sell Cosentyx for the treatment of Hidradenitis Suppurativa. This could potentially increase Novartis' market share in the pharmaceutical industry and boost its revenue, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100